[Current Status of ctDNA-Based MRD Testing in Breast Cancer]

Treatment strategies for breast cancer are becoming increasingly complex, necessitating a deeper understanding of the disease and the personalization of therapy based on biomarkers. Circulating tumor DNA(ctDNA)allows for comprehensive tumor assessment in a minimally invasive manner, and therapeutic development in this area is actively progressing. Studies evaluating ctDNA during postoperative follow-up or after neoadjuvant chemotherapy across various breast cancer subtypes have consistently shown that ctDNA detection is associated with a higher risk of recurrence, regardless of the clinical setting. Clinical trials investigating therapeutic interventions guided by ctDNA testing are currently underway. Moving forward, the development of more sensitive assay and effective therapeutic strategies is needed. The clinical application of ctDNA is expected to further advance personalized treatment in breast cancer.